Business context and reporting period
Neogen Corporation develops and sells food-safety testing products and animal-safety products and services. This Form 10-K covers the fiscal year ended May 31, 2022, with comparisons to fiscal 2021 and 2020; it is not a standalone 2021 Q4 report. Amounts below are in U.S. dollars.
The company reports Food Safety and Animal Safety segments. Fiscal 2022 revenue was nearly evenly split: Food Safety $260.0 million and Animal Safety $267.2 million. International sales were $209.3 million, or 39.7% of revenue.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $527.2 million | $468.5 million | +13% |
| Gross margin | $243.0 million; 46.1% | $215.1 million; 45.9% | Margin +0.2 percentage points |
| Operating income | $58.6 million; 11.1% margin | $74.2 million; 15.8% margin | -21% |
| Net income | $48.3 million | $60.9 million | -21% |
| Diluted EPS | $0.45 | $0.57 | Down from prior year |
| Cash from operations | $68.0 million | $81.1 million | Down $13.1 million |
| Adjusted EBITDA (non-GAAP) | $115.4 million; 21.9% margin | $104.2 million; 22.2% margin | +11%; margin -0.3 points |
Revenue growth was broad-based: Food Safety increased 11% and Animal Safety 14%. Organic sales growth was 7% and 12%, respectively. Notable category increases included veterinary instruments and disposables (+33%) and culture media and other (+23%); Food Safety natural toxins, allergens and drug residues grew 4%, including a 33% decline in drug-residue test-kit sales.
Cost of revenue was 53.9% of revenue versus 54.1% in FY2021. Management attributed modest consolidated gross-margin improvement to Animal Safety product mix, partly offset by higher raw-material and freight costs. Operating expenses rose 31%, principally reflecting $25.6 million of 3M transaction-related legal, consulting and other professional fees. Excluding those costs, management said operating income rose 13% and net income would have been $67.9 million, up 12% after adjusting taxes.
At May 31, 2022, cash and cash equivalents were $44.5 million, marketable securities $336.6 million, working capital $549.0 million and total assets $992.9 million. The company had no borrowings under its $15 million unsecured revolving credit line and reported no long-term debt. Operating cash flow was used alongside $24.4 million of purchases of property, equipment and other non-current assets and $38.7 million for acquisitions. Inventory rose 21% to $122.3 million, partly to buffer supply constraints; receivables were $99.7 million, and days sales outstanding improved to 62 from 66.
Material changes, outlook and risks
- Proposed 3M Food Safety transaction: Announced in December 2021 as a Reverse Morris Trust. Existing Neogen shareholders were expected to own about 49.9% of the combined company and Garden SpinCo shareholders about 50.1%. The filing estimated an enterprise value of approximately $3.4 billion, based on Neogen’s July 22, 2022 share price, including $1 billion of new debt. Closing was expected by the end of calendar Q3 2022, subject to shareholder, regulatory and other conditions. The filing warns of integration, financing, dilution and transaction-completion risks; a $140 million termination fee could apply in certain circumstances.
- Proposed transaction financing: Garden SpinCo entered into a $650 million five-year senior secured term loan and a $150 million revolving facility in June 2022. A $350 million offering of 8.625% senior notes due 2030 was completed in July 2022. Upon closing, the notes were expected to be guaranteed by Neogen and certain subsidiaries, and the new financing would materially change the company’s debt profile.
- Cost and demand pressures: Management reported higher transportation, supply-chain, raw-material and labor costs in FY2022. Pricing actions offset some, but not all, inflation. Inflation was expected to continue affecting FY2023, but the impact was not quantifiable. COVID-19 continued to weaken demand in some food-service-related customer markets and disrupt labor, shipping and supply; management expected effects through at least FY2023.
- Geopolitical exposure: The company discontinued sales to Russia and Belarus following Russia’s invasion of Ukraine. It reported intermittent material shortages and higher transportation, energy and raw-material costs, and warned that worsening conflict or sanctions could further affect costs and sales.
- Investment plans: Management expected annual R&D spending of about 3%–4% of revenue and anticipated several new or improved products during FY2023 and FY2024. Estimated FY2023 capital expenditures for existing operations were $20–$25 million; additional plans included approximately $70 million for a manufacturing facility and $50 million for an ERP system over the next two fiscal years, plus $3–$5 million of FY2023 transaction-related facility improvements and capital leases. These are estimates, not earnings guidance.
- Contingencies: An OFAC investigation concerns certain genomic testing services connected to an Iranian party. Neogen had a $0.6 million reserve and stated that it believed the amount adequate, while the outcome remained uncertain. A Wisconsin facility remediation liability was $0.916 million; alternative remediation could increase future costs. Management did not expect ordinary-course legal proceedings to have a material effect.
- Other risks: The filing highlights acquisition integration, supplier and supply-chain dependence, competition, regulation, intellectual-property protection, cybersecurity, foreign-exchange exposure, agricultural-market cycles and retention of key employees. No cash dividend was expected in the foreseeable future.
The company reported effective disclosure controls and internal control over financial reporting. The auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether the 3M transaction closed as expected, its final consideration and ownership split, and the combined company’s actual debt, interest expense and integration costs.
- Whether organic growth and pricing can offset inflation, supply-chain and labor costs, and whether reported margin trends persist after transaction expenses.
- Whether the elevated inventory converts to sales without meaningful obsolescence or write-downs, and whether operating cash flow recovers.
- Outcomes of the OFAC investigation and Wisconsin remediation pilot, including any change to reserves or additional cash obligations.
- Progress and actual spending against the announced manufacturing and ERP investment plans, and the commercial performance of anticipated new products.